FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.
You may also be interested in...
"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon
The agency is planning a library of validated computer models of how patients respond to medical treatments.
"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon
The agency is planning a library of validated computer models of how patients respond to medical treatments.
Regulatory Science Next To Be Outsourced?
CDER report calls for broader partnerships with outside bodies in regulatory science.